Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.55 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.55 |
| ▸ | CCR2 | P41597 | 1/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7179044 | 0.94 | HRH3 (0.67) | HRH3SMN1; SMN2GAAROCK1ROCK2 | |
| SCHEMBL4855546 | 0.87 | HRH3 (0.74) | HRH3SMN1; SMN2GAAROCK1ROCK2 | |
| SCHEMBL5203366 | 0.86 | HRH3 (0.69) | HRH3SMN1; SMN2GAAROCK1ROCK2 | |
| SCHEMBL5202949 | 0.85 | HRH3 (0.70) | HRH3SMN1; SMN2GAA | |
| SCHEMBL7179085 | 0.85 | HRH3 (0.62) | HRH3SMN1; SMN2GAAMAOAMAOB | |
| SCHEMBL7197267 | 0.85 | HRH3 (0.65) | HRH3SMN1; SMN2GAAMAOAMAOB | |
| SCHEMBL13463052 | 0.84 | HRH3 (0.70) | HRH3SMN1; SMN2GAAROCK1ROCK2 | |
| SCHEMBL5202774 | 0.84 | HRH3 (0.76) | HRH3SMN1; SMN2GAA | |
| SCHEMBL3022526 | 0.84 | HRH3 (0.71) | HRH3SMN1; SMN2GAAROCK1ROCK2 | |
| SCHEMBL8393625 | 0.84 | HRH3 (0.71) | HRH3SMN1; SMN2GAAROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241778-B2 | Non-imidazole aryloxypiperidines | ORTHO MCNEIL PHARMACEUTICAL, INC (US) | 2007-07-10 | — | — | US | disclosed |
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-1311482-B1 | NON-IMIDAZOLE ARYLOXYPIPERIDINES AS H3 RECEPTOR LIGANDS | ORTHO MCNEIL PHARM INC (US) | 2007-02-21 | — | — | EP | disclosed |
| US-7071191-B2 | Non-imidazole aryloxypiperidines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | APODACA RICHARD | 2005-10-13 | — | — | US | disclosed |
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | NORTEL NETWORKS LIMITED (CA) | 2002-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040024-A1 | Non-imidazole aryloxypiperidines | HRH2, HRH4, HRH3 | HRH3 3/4885SMN1; SMN2 3177/4885GAA 1168/4885 |
| US-20050227979-A1 | Non-imidazole aryloxypiperidines | HRH2, HRH4, HRH3 | HRH3 3/4885SMN1; SMN2 3177/4885GAA 1168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.